- Home
- NGNE vs CLPT Comparison
NGNE vs CLPT Comparison
Compare NGNE & CLPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- CLPT
- Stock Information
- Founded
- NGNE 2003
- CLPT 1998
- Country
- NGNE United States
- CLPT United States
- Employees
- NGNE N/A
- CLPT N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- CLPT Medical/Dental Instruments
- Sector
- NGNE Health Care
- CLPT Health Care
- Exchange
- NGNE Nasdaq
- CLPT Nasdaq
- Market Cap
- NGNE 251.9M
- CLPT 315.7M
- IPO Year
- NGNE N/A
- CLPT N/A
- Fundamental
- Price
- NGNE $20.09
- CLPT $11.69
- Analyst Decision
- NGNE Strong Buy
- CLPT Strong Buy
- Analyst Count
- NGNE 7
- CLPT 3
- Target Price
- NGNE $41.86
- CLPT $27.67
- AVG Volume (30 Days)
- NGNE 240.1K
- CLPT 526.5K
- Earning Date
- NGNE 08-08-2025
- CLPT 08-06-2025
- Dividend Yield
- NGNE N/A
- CLPT N/A
- EPS Growth
- NGNE N/A
- CLPT N/A
- EPS
- NGNE N/A
- CLPT N/A
- Revenue
- NGNE $925,000.00
- CLPT $32,235,999.00
- Revenue This Year
- NGNE N/A
- CLPT $23.97
- Revenue Next Year
- NGNE N/A
- CLPT $27.52
- P/E Ratio
- NGNE N/A
- CLPT N/A
- Revenue Growth
- NGNE N/A
- CLPT 23.22
- 52 Week Low
- NGNE $6.88
- CLPT $5.24
- 52 Week High
- NGNE $74.49
- CLPT $19.22
- Technical
- Relative Strength Index (RSI)
- NGNE 57.57
- CLPT 39.44
- Support Level
- NGNE $14.65
- CLPT $11.02
- Resistance Level
- NGNE $18.21
- CLPT $12.38
- Average True Range (ATR)
- NGNE 1.84
- CLPT 0.55
- MACD
- NGNE 0.03
- CLPT -0.02
- Stochastic Oscillator
- NGNE 80.24
- CLPT 27.91
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.